NCT03553615

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

Detailed description

OBJECTIVES: I. Overall response rate of atopic dermatitis in subjects as assessed using Dermatology Life Quality Index (a 10 question questionnaire used to measure the impact of skin disease on the quality of life of an affected person) SECONDARY OBJECTIVES: I. , Eczema Area and Severity Index (EASI), Total Severity Scoring (TSS) II. Safety assessment after 8 weeks with 4 weeks of oral treatment. III. VAS (Visual Analogue Scale, an instrument for the assessment of pruritus) at baseline through eight weeks. OUTLINE: Patients receiving novel oral agent once a week for 4 weeks in the absence of disease progression or unacceptable toxicity.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Ivermectin Pill	oral anti-parasitic agent taken as a weekly dose for four weeks

Timeline

• Start date: 2030-12-01
• Primary completion: 2030-12-01
• Completion: 2030-12-01
• First posted: 2018-06-12
• Last updated: 2024-12-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study